Tag Archives: Biotech IPOs

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and biotech sectors alike. Last year, generalists in many ways capitulated

We’ve now entered the 46th straight quarter of biotech IPO activity. New equity issuance for biotech in 2021 has broken records for the amount of capital raised, topping even the strong years of 2020 and 2014. Although the open and

2018 was a incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits

The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a

Although many wrote off the biotech IPO markets as moribund earlier in 2016, the sector has been quietly issuing a steady stream of new offerings. Despite the volatility related to drug pricing, and disastrous first six-weeks of the year, we’ve

After five very strong years, biotech as a sector has struggled to catalyze positive investor sentiment so far for the past twelve months. In a disastrous start to the year, the NASDAQ Biotech Index shed 30% in just the first

Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small

As one of big drivers behind the recent IPO window, cross-over investing into private biotech companies by both mutual fund and hedge fund investors has become increasingly commonplace over the past couple years.  As described at the BIO Investor meeting

With the biotech IPO window still open for business, and valuations of the recent classes of 2013 and 2014 remaining robust, all eyes have been focused on this part of the value chain.  Significant mezzanine pre-IPO rounds are getting done

As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets.   2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000.  Last week

The biotech IPO bonanza appears to be continuing into 2014, with over thirteen offerings already this year.  We’re just now completing the busiest two week period in biotech IPOs ever.  Another dozen or so companies appear likely to price IPOs

The past year has certainly been the most exciting one for Biotech IPOs since 2000, with dozens of new offerings and compelling therapeutic narratives.  But focusing on these new IPOs misses an equal if not more exciting story: the significant

Six months ago the biotech industry was on the verge of a sizzling season for IPOs, and since then, on average, we’ve seen one new biotech IPO per week.  Valuations of many of these offerings have been impressive, and this

As you might expect given the strong IPO market, biotech venture investors are doing less of the heavy lifting in support of their portfolio companies during this receptive climate than in the past few years. Biotech insider participation was the

Biotech is back with a vengeance in this IPO window.  After a decade drought, we’ve witnessed over 30 new biotech offerings this year and more than $2.5B raised – the best IPO market since 2000.  In fact, it’s already the